ALS
The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners.
GenieUs Genomics Aims to Stratify ALS Patients Using Bioinformatics Platform, Long-Read Sequencing
Premium
The Australian firm seeks to validate its DiGAP platform in a clinical study by categorizing ALS patients according to their most affected biological pathways.
Target ALS and DNAstack developed the portal as a streamlined way for researchers to store, query, and analyze data all in one place.
NeuroSense, Lonza Partner to Identify Exosome-Based Neurodegenerative Disease Biomarkers
The collaboration will initially support further development of NeuroSense's lead amyotrophic lateral sclerosis drug candidate, PrimeC.
PrecisionLife, Metrodora Institute Partner on Chronic Disease Dx, Treatments
The firms plan to develop new diagnostics that identify patient risk of chronic diseases and study existing medicines that could be repurposed as treatments.
Jun 17, 2021
New ALS Risk Gene Suggests Role for Apoptosis
Feb 28, 2020
Medidata, Project ALS Form Research Alliance
Sep 7, 2018
Jul 24, 2018
Jul 16, 2018
Verge Genomics Scores $32M in Series A Round
Nov 21, 2017